Intelligent Bio Solutions Inc. (NASDAQ:INBS) Short Interest Down 10.0% in November

Intelligent Bio Solutions Inc. (NASDAQ:INBS) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 508,200 shares, a decrease of 10.0% from the November 15th total of 564,600 shares. Currently, 11.9% of the company’s stock are short sold. Based on an average trading volume of 287,400 shares, the short-interest ratio is currently 1.8 days.

Intelligent Bio Solutions Price Performance

NASDAQ:INBS opened at $1.47 on Tuesday. The firm has a fifty day simple moving average of $1.55 and a 200 day simple moving average of $1.63. Intelligent Bio Solutions has a 1-year low of $1.00 and a 1-year high of $11.70.

Intelligent Bio Solutions (NASDAQ:INBS) last announced its earnings results on Thursday, November 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.17). The business had revenue of $872.29 million for the quarter. Intelligent Bio Solutions had a negative return on equity of 147.50% and a negative net margin of 288.35%. As a group, equities research analysts predict that Intelligent Bio Solutions will post -1.25 earnings per share for the current fiscal year.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.